Connective tissue disease associated interstitial lung disease
Conditions
Interventions
Case group:None
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Prospective Cohort Study: 1. Gender is not limited, between the ages of 18 and 80; 2. The patient has signed an informed consent form agreeing to the use of information about their condition; 3. Patients diagnosed with the following diseases: rheumatoid arthritis-related interstitial lung disease (RA-ILD), idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD), systemic sclerosis-associated interstitial lung disease (SSc-ILD), Sjögren's syndrome-related interstitial lung disease (SS-ILD); 4. The clinical diagnosis of interstitial lung disease (ILD) confirmed by high-resolution computed tomography (HRCT) was jointly confirmed by multidisciplinary physicians from radiology, respiratory, and rheumatology and immunology. Retrospective cohort study: 1. Medical records of patients who can be collected after evaluation from 2013 to the study start date; 2. Medical records of male and female, patients over 18 years of age; 3. The patient's medical record containing at least the following information: patient's initial, date of birth, gender, date of diagnosis, complete diagnosis information; 4. Patients diagnosed with the following diseases: rheumatoid arthritis (RA), idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc), Sjögren's syndrome (SS) (confirmed CTD-ILD according to the diagnostic criteria [including pathological diagnosis] of the medical record period); 5. The clinical diagnosis of interstitial lung disease (ILD) confirmed by high-resolution computed tomography (HRCT) was jointly confirmed by multidisciplinary physicians from radiology, respiratory, and rheumatology and immunology.
Exclusion criteria
Exclusion criteria: 1. Meeting two or more classification criteria for connective tissue diseases; 2. Having comorbid conditions such as pulmonary infections, pulmonary edema, lung malignancies, or other lung diseases; 3. Having unclear diagnostic information, such as the lack of traceable HRCT diagnostic information; 4. Patients who are unwilling to participate in the study or do not have the ability to complete the follow-up for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progressive pulmonary fibrosis,PPF; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dyspnea worsens;Number of deaths; | — |
Countries
China
Contacts
Public ContactMengtao Li
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed